0001683168-23-002852.txt : 20230502
0001683168-23-002852.hdr.sgml : 20230502
20230502161508
ACCESSION NUMBER: 0001683168-23-002852
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20230502
DATE AS OF CHANGE: 20230502
EFFECTIVENESS DATE: 20230502
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp.
CENTRAL INDEX KEY: 0001533040
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-480606
FILM NUMBER: 23879197
BUSINESS ADDRESS:
STREET 1: 257 SIMARANO DRIVE
STREET 2: SUITE 101
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
BUSINESS PHONE: (508) 767-3861
MAIL ADDRESS:
STREET 1: 257 SIMARANO DRIVE
STREET 2: SUITE 101
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
FORMER COMPANY:
FORMER CONFORMED NAME: RXi Pharmaceuticals Corp
DATE OF NAME CHANGE: 20111019
D
1
primary_doc.xml
X0708
D
LIVE
0001533040
Phio Pharmaceuticals Corp.
257 SIMARANO DRIVE
SUITE 101
MARLBOROUGH
MA
MASSACHUSETTS
01752
508-929-3861
DELAWARE
RXi Pharmaceuticals Corp.
RXi Pharmaceuticals Corp
Corporation
true
Robert
J.
Bitterman
257 Simarano Drive
Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Executive Officer
Director
Patricia
A.
Bradford
257 Simarano Drive
Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Geert
Cauwenbergh
257 Simarano Drive
Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Robert
L.
Ferrara
257 Simarano Drive
Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Jonathan
E.
Freeman
257 Simarano Drive
Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Curtis
A.
Lockshin
257 Simarano Drive
Suite 101
Marlborough
MA
MASSACHUSETTS
01752
Director
Biotechnology
No Revenues
- 06b
false
2023-04-20
false
true
true
false
0
H.C. Wainwright & Co., LLC
375
None
None
430 PARK AVENUE
3RD FLOOR
NEW YORK
NY
NEW YORK
10022
IL
ILLINOIS
NY
NEW YORK
TX
TEXAS
false
4010519
4010519
0
Both amounts reflect the aggregate exercise price due to the Company assuming full cash exercise of all warrants issued to the accredited and institutional investors and the placement agent in the privateplacement in reliance on Rule 506(b).
false
3
245950
0
In connection with the registered direct offering concurrent with the private placement, the placement agent received $245,950 and warrants to purchase up to 26,549 shares of common stock exercisable at $7.06 per share.
0
false
Phio Pharmaceuticals Corp.
/s/ Robert Bitterman
Robert Bitterman
President and Chief Executive Officer
2023-05-02